Sean Keohane Sells 134,895 Shares of Cabot (NYSE:CBT) Stock

Cabot Corporation (NYSE:CBT) CEO Sean Keohane sold 134,895 shares of the firm’s stock in a transaction on Friday, August 28th. The stock was sold at an average price of $85.00, for a total value of $11,466,075.00. Following the completion of the sale, the chief executive officer directly owned 404,134 shares of the company’s stock, valued at $34,351,390. This trade represents a 25.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Cabot Stock Down 2.6%

NYSE CBT opened at $80.56 on Wednesday. The business’s fifty day simple moving average is $87.32 and its 200-day simple moving average is $81.32. The company has a quick ratio of 0.97, a current ratio of 1.47 and a debt-to-equity ratio of 0.48. The firm has a market cap of $4.16 billion, a PE ratio of 22.69, a P/E/G ratio of 10.86 and a beta of 0.84. Cabot Corporation has a 52 week low of $58.33 and a 52 week high of $94.53.

Cabot (NYSE:CBT) last released its quarterly earnings data on Monday, August 3rd. The specialty chemicals company reported $1.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.66 by $0.01. Cabot had a net margin of 5.23% and a return on equity of 20.29%. The firm had revenue of $982.00 million during the quarter, compared to analysts’ expectations of $943.16 million. During the same period last year, the business earned $1.90 earnings per share. Cabot’s revenue was up 6.4% compared to the same quarter last year. Cabot has set its FY 2026 guidance at 6.150-6.450 EPS. As a group, equities analysts anticipate that Cabot Corporation will post 6.35 earnings per share for the current year.

Cabot Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 28th will be issued a dividend of $0.4725 per share. The ex-dividend date is Friday, August 28th. This represents a $1.89 dividend on an annualized basis and a dividend yield of 2.3%. Cabot’s dividend payout ratio (DPR) is currently 53.24%.

Analysts Set New Price Targets

CBT has been the topic of a number of recent analyst reports. Wall Street Zen upgraded Cabot from a “hold” rating to a “buy” rating in a report on Sunday, August 9th. UBS Group cut their target price on Cabot from $97.00 to $92.00 and set a “neutral” rating for the company in a research note on Wednesday, August 5th. JPMorgan Chase & Co. lifted their target price on Cabot from $70.00 to $78.00 and gave the company an “underweight” rating in a research report on Friday, August 7th. Mizuho upped their price target on Cabot from $80.00 to $90.00 and gave the company a “neutral” rating in a research note on Thursday, June 25th. Finally, Truist Financial set a $100.00 price target on Cabot in a report on Wednesday, August 5th. Two research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $89.00.

Hedge Funds Weigh In On Cabot

Large investors have recently made changes to their positions in the stock. NewEdge Advisors LLC increased its holdings in Cabot by 2,559.5% in the 1st quarter. NewEdge Advisors LLC now owns 984 shares of the specialty chemicals company’s stock valued at $82,000 after purchasing an additional 947 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Cabot by 32.5% during the first quarter. Goldman Sachs Group Inc. now owns 442,646 shares of the specialty chemicals company’s stock worth $36,802,000 after buying an additional 108,645 shares during the period. Empowered Funds LLC grew its stake in shares of Cabot by 102.6% in the first quarter. Empowered Funds LLC now owns 28,162 shares of the specialty chemicals company’s stock valued at $2,341,000 after buying an additional 14,260 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Cabot by 3.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 122,022 shares of the specialty chemicals company’s stock valued at $10,145,000 after buying an additional 4,048 shares in the last quarter. Finally, Geneos Wealth Management Inc. raised its holdings in shares of Cabot by 409.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 453 shares of the specialty chemicals company’s stock valued at $38,000 after buying an additional 364 shares during the period. 93.18% of the stock is currently owned by institutional investors and hedge funds.

Cabot Company Profile

Cabot Corporation is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. Founded in 1882 by Godfrey Lowell Cabot, the company has grown into a diversified manufacturer with operations across North America, Europe, Asia and Latin America. Cabot serves a wide range of end markets, including automotive, industrial, energy, and consumer products, supplying essential ingredients that enhance performance, durability and functionality.

The company operates two primary segments: Reinforcement Materials and Performance Materials.